Otometrics Unveils the Next Generation Bio-logic solutions

​Otometrics has introduced the next generation Bio-logic® solutions. Bio-logic has been the trusted brand among professionals for easy-to-use and accurate hearing diagnostics and screening since 1979. Natus Medical Incorporated acquired Bio-logic in 2006 and today Otometrics is reintroducing this legacy brand as part of its global portfolio. "Bio-logic is a well-loved brand with a proud legacy of providing reliable testing," said Mona Dworsack, AuD, Global Director of Product Management, Hearing Assessment and Screening."Our innovation is inspired by the professional’s work flow. Our next generation Bio-logic products offer a range of test combinations in a single device – so it’s easy to adapt to changing patient needs.” 

Bio-logic diagnostic solutions are especially well suited for audiologists who need space-saving devices that are efficient and flexible. Powered by advanced modular technology, the next generation Bio-logic allows screeners to choose a test combination to suit the needs of their clinic​. Four new Bio-logic products will be on display at AAA 2018 booth #621. The products are available for sale in select countries at the conclusion of the conference. Existing Bio-logic users and Otometrics customers are encouraged to contact their local Otometrics/Audiology Systems representatives to start customizing their next generation Bio-logic solution. 

Published: 4/13/2018 5:50:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2H0vNPM
via IFTTT

Eosera to Expand Cerumen Removal Product Line

​Eosera (https://earcaremd.com/), the maker of Earwax MD, is releasing new cerumen-targeted products, and will be offering a sneak peek at all the new products at AudiologyNow! 2018 in Nashville, TN. Among Eosera's new products to be unveiled is WaxBlaster MD, a rinsing device to be used after cleaning the ear canal with Earwax MD. Elyse Dickerson, co-founder and CEO of Eosera, said the market has responded well to Earwax MD since last year when it was first introduced. "In retailers carrying the product, dollar sales are up over 18 percent in the ear care category. This growth is primarily driven by the introduction of Earwax MD," Dickerson said. Eosera will sell the products directly and via various resellers for sale in-clinic. At AudiologyNow! 2018, attendees can find out more about Earwax MD and Eosera's new products, including WaxBlaster MD, at Booth 434​. 

Published: 4/13/2018 5:47:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2qAAVPD
via IFTTT

Promising drug may deter hearing loss, study finds

A new drug has the potential to revolutionize the prevention and treatment of hearing loss resulting from noise, drug toxicity, and possibly aging, researchers at St. Jude Children's Research Hospital claims. The researchers discovered inhibitors of enzyme Cyclin-dependent kinase 2 (CDK2) that may protect people from developing hearing loss, including hearing impairment in the elderly population.

The study's lead author Jian Zuo, PhD told The Hearing Journal, "We have reported a genomic study that identified a predisposition to cisplatin-induced hearing loss (CIHL) among pediatric brain tumor patients (Xu et al., Nature Genetics 2015). While predicting which patients will develop CIHL is important, it is more imperative to develop drugs to prevent CIHL. There are no FDA-approved drugs for hearing loss. It is these thoughts that inspired us to screen for drugs against CIHL."

The researchers developed an approach to mimic mammalian cochlear cell death caused by antibiotics, noise, aging, and cisplatin to discover otoprotectants. Cisplatin is a chemotherapy agent, a treatment for an array of cancers, reported to cause permanent hearing loss in patients.

Examining a bioactive library of more than 4,000 unique compounds of an immortalized cell from a cochlear cell line of a neonatal mouse, study authors found ten compounds with protective effects against cisplatin ototoxicity. Among the top-hit compounds was kenpaullone, an inhibitor of CDK2 and other kinases, which are found in zebrafish, adult mice, and rats. Kenpaullone was found to deter cisplatin- and noise-induced damage.

"Our compounds are protective [not only] against CIHL but also noise-induced hearing loss (NIHL). It is also likely that it protects against age-related hearing loss (ARHL)," Zuo explained. "Both NIHL and ARHL affect a large fraction of the society. Based on our results in an identical assay, our compound exhibits better protection against cisplatin-induced cell loss than four benchmark compounds currently in clinical trials. Therefore we believe that our compound will eventually fare well in future clinical trials."

When asked if the CDK2 inhibitors can help patients with inborn hearing loss, Zuo explained, "Our compounds will protect HL but have not been shown to restore hearing among patients with congenital deafness."

The researchers have filed a patent on the methods and the compositions of the CDK2 inhibitors that are discovered to prevent cisplatin- and noise-induced hearing loss.

Published: 4/10/2018 1:27:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2H0dlXr
via IFTTT

Otometrics Unveils the Next Generation Bio-logic solutions

​Otometrics has introduced the next generation Bio-logic® solutions. Bio-logic has been the trusted brand among professionals for easy-to-use and accurate hearing diagnostics and screening since 1979. Natus Medical Incorporated acquired Bio-logic in 2006 and today Otometrics is reintroducing this legacy brand as part of its global portfolio. "Bio-logic is a well-loved brand with a proud legacy of providing reliable testing," said Mona Dworsack, AuD, Global Director of Product Management, Hearing Assessment and Screening."Our innovation is inspired by the professional’s work flow. Our next generation Bio-logic products offer a range of test combinations in a single device – so it’s easy to adapt to changing patient needs.” 

Bio-logic diagnostic solutions are especially well suited for audiologists who need space-saving devices that are efficient and flexible. Powered by advanced modular technology, the next generation Bio-logic allows screeners to choose a test combination to suit the needs of their clinic​. Four new Bio-logic products will be on display at AAA 2018 booth #621. The products are available for sale in select countries at the conclusion of the conference. Existing Bio-logic users and Otometrics customers are encouraged to contact their local Otometrics/Audiology Systems representatives to start customizing their next generation Bio-logic solution. 

Published: 4/13/2018 5:50:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2H0vNPM
via IFTTT

Eosera to Expand Cerumen Removal Product Line

​Eosera (https://earcaremd.com/), the maker of Earwax MD, is releasing new cerumen-targeted products, and will be offering a sneak peek at all the new products at AudiologyNow! 2018 in Nashville, TN. Among Eosera's new products to be unveiled is WaxBlaster MD, a rinsing device to be used after cleaning the ear canal with Earwax MD. Elyse Dickerson, co-founder and CEO of Eosera, said the market has responded well to Earwax MD since last year when it was first introduced. "In retailers carrying the product, dollar sales are up over 18 percent in the ear care category. This growth is primarily driven by the introduction of Earwax MD," Dickerson said. Eosera will sell the products directly and via various resellers for sale in-clinic. At AudiologyNow! 2018, attendees can find out more about Earwax MD and Eosera's new products, including WaxBlaster MD, at Booth 434​. 

Published: 4/13/2018 5:47:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2qAAVPD
via IFTTT

Promising drug may deter hearing loss, study finds

A new drug has the potential to revolutionize the prevention and treatment of hearing loss resulting from noise, drug toxicity, and possibly aging, researchers at St. Jude Children's Research Hospital claims. The researchers discovered inhibitors of enzyme Cyclin-dependent kinase 2 (CDK2) that may protect people from developing hearing loss, including hearing impairment in the elderly population.

The study's lead author Jian Zuo, PhD told The Hearing Journal, "We have reported a genomic study that identified a predisposition to cisplatin-induced hearing loss (CIHL) among pediatric brain tumor patients (Xu et al., Nature Genetics 2015). While predicting which patients will develop CIHL is important, it is more imperative to develop drugs to prevent CIHL. There are no FDA-approved drugs for hearing loss. It is these thoughts that inspired us to screen for drugs against CIHL."

The researchers developed an approach to mimic mammalian cochlear cell death caused by antibiotics, noise, aging, and cisplatin to discover otoprotectants. Cisplatin is a chemotherapy agent, a treatment for an array of cancers, reported to cause permanent hearing loss in patients.

Examining a bioactive library of more than 4,000 unique compounds of an immortalized cell from a cochlear cell line of a neonatal mouse, study authors found ten compounds with protective effects against cisplatin ototoxicity. Among the top-hit compounds was kenpaullone, an inhibitor of CDK2 and other kinases, which are found in zebrafish, adult mice, and rats. Kenpaullone was found to deter cisplatin- and noise-induced damage.

"Our compounds are protective [not only] against CIHL but also noise-induced hearing loss (NIHL). It is also likely that it protects against age-related hearing loss (ARHL)," Zuo explained. "Both NIHL and ARHL affect a large fraction of the society. Based on our results in an identical assay, our compound exhibits better protection against cisplatin-induced cell loss than four benchmark compounds currently in clinical trials. Therefore we believe that our compound will eventually fare well in future clinical trials."

When asked if the CDK2 inhibitors can help patients with inborn hearing loss, Zuo explained, "Our compounds will protect HL but have not been shown to restore hearing among patients with congenital deafness."

The researchers have filed a patent on the methods and the compositions of the CDK2 inhibitors that are discovered to prevent cisplatin- and noise-induced hearing loss.

Published: 4/10/2018 1:27:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2H0dlXr
via IFTTT

Otometrics Unveils the Next Generation Bio-logic solutions

​Otometrics has introduced the next generation Bio-logic® solutions. Bio-logic has been the trusted brand among professionals for easy-to-use and accurate hearing diagnostics and screening since 1979. Natus Medical Incorporated acquired Bio-logic in 2006 and today Otometrics is reintroducing this legacy brand as part of its global portfolio. "Bio-logic is a well-loved brand with a proud legacy of providing reliable testing," said Mona Dworsack, AuD, Global Director of Product Management, Hearing Assessment and Screening."Our innovation is inspired by the professional’s work flow. Our next generation Bio-logic products offer a range of test combinations in a single device – so it’s easy to adapt to changing patient needs.” 

Bio-logic diagnostic solutions are especially well suited for audiologists who need space-saving devices that are efficient and flexible. Powered by advanced modular technology, the next generation Bio-logic allows screeners to choose a test combination to suit the needs of their clinic​. Four new Bio-logic products will be on display at AAA 2018 booth #621. The products are available for sale in select countries at the conclusion of the conference. Existing Bio-logic users and Otometrics customers are encouraged to contact their local Otometrics/Audiology Systems representatives to start customizing their next generation Bio-logic solution. 

Published: 4/13/2018 5:50:00 PM

from #Audiology via xlomafota13 on Inoreader https://ift.tt/2H0vNPM
via IFTTT

Eosera to Expand Cerumen Removal Product Line

​Eosera (https://earcaremd.com/), the maker of Earwax MD, is releasing new cerumen-targeted products, and will be offering a sneak peek at all the new products at AudiologyNow! 2018 in Nashville, TN. Among Eosera's new products to be unveiled is WaxBlaster MD, a rinsing device to be used after cleaning the ear canal with Earwax MD. Elyse Dickerson, co-founder and CEO of Eosera, said the market has responded well to Earwax MD since last year when it was first introduced. "In retailers carrying the product, dollar sales are up over 18 percent in the ear care category. This growth is primarily driven by the introduction of Earwax MD," Dickerson said. Eosera will sell the products directly and via various resellers for sale in-clinic. At AudiologyNow! 2018, attendees can find out more about Earwax MD and Eosera's new products, including WaxBlaster MD, at Booth 434​. 

Published: 4/13/2018 5:47:00 PM

from #Audiology via xlomafota13 on Inoreader https://ift.tt/2qAAVPD
via IFTTT

Promising drug may deter hearing loss, study finds

A new drug has the potential to revolutionize the prevention and treatment of hearing loss resulting from noise, drug toxicity, and possibly aging, researchers at St. Jude Children's Research Hospital claims. The researchers discovered inhibitors of enzyme Cyclin-dependent kinase 2 (CDK2) that may protect people from developing hearing loss, including hearing impairment in the elderly population.

The study's lead author Jian Zuo, PhD told The Hearing Journal, "We have reported a genomic study that identified a predisposition to cisplatin-induced hearing loss (CIHL) among pediatric brain tumor patients (Xu et al., Nature Genetics 2015). While predicting which patients will develop CIHL is important, it is more imperative to develop drugs to prevent CIHL. There are no FDA-approved drugs for hearing loss. It is these thoughts that inspired us to screen for drugs against CIHL."

The researchers developed an approach to mimic mammalian cochlear cell death caused by antibiotics, noise, aging, and cisplatin to discover otoprotectants. Cisplatin is a chemotherapy agent, a treatment for an array of cancers, reported to cause permanent hearing loss in patients.

Examining a bioactive library of more than 4,000 unique compounds of an immortalized cell from a cochlear cell line of a neonatal mouse, study authors found ten compounds with protective effects against cisplatin ototoxicity. Among the top-hit compounds was kenpaullone, an inhibitor of CDK2 and other kinases, which are found in zebrafish, adult mice, and rats. Kenpaullone was found to deter cisplatin- and noise-induced damage.

"Our compounds are protective [not only] against CIHL but also noise-induced hearing loss (NIHL). It is also likely that it protects against age-related hearing loss (ARHL)," Zuo explained. "Both NIHL and ARHL affect a large fraction of the society. Based on our results in an identical assay, our compound exhibits better protection against cisplatin-induced cell loss than four benchmark compounds currently in clinical trials. Therefore we believe that our compound will eventually fare well in future clinical trials."

When asked if the CDK2 inhibitors can help patients with inborn hearing loss, Zuo explained, "Our compounds will protect HL but have not been shown to restore hearing among patients with congenital deafness."

The researchers have filed a patent on the methods and the compositions of the CDK2 inhibitors that are discovered to prevent cisplatin- and noise-induced hearing loss.

Published: 4/10/2018 1:27:00 PM

from #Audiology via xlomafota13 on Inoreader https://ift.tt/2H0dlXr
via IFTTT

Repeated Audiometry After Bacterial Meningitis: Consequences for Future Management

Objective: Sensorineural hearing loss is a common sequela of bacterial meningitis. The objective of this study is to delineate the incidence and course of hearing loss after bacterial meningitis. Study Design: Retrospective cohort study. Setting: Tertiary referral center. Patients: Data of 655 patients who suffered from bacterial meningitis between 1985 and 2015 were analyzed. Interventions: None. Main Outcome Measurements: Availability of audiometric data, incidence of hearing loss, and onset and course of hearing loss. Results: In this cohort the incidence of hearing loss (>25 dB) was 28% (95% confidence interval 23–34%). The incidence of profound hearing loss (>80 dB) was 13% (95% confidence interval 10–18%). Normal hearing at the first assessment after treatment for meningitis remained stable over time in all these patients. In 19 of the 28 patients with diagnosed hearing loss, the hearing level remained stable over time. Hearing improved in six patients and deteriorated in two patients. One patient showed a fluctuating unilateral hearing loss. Conclusion: Audiological tests in patients with bacterial meningitis, especially children, should be started as soon as possible after the acute phase is over. As we found no deterioration of initial normal hearing after bacterial meningitis, repeated audiometry seems indicated only for those with diagnosed hearing loss at first assessment. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. https://ift.tt/OBJ4xP Address correspondence and reprint requests to Marc P. van der Schroeff, Ph.D., Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus Medical Center, Room SP-1455, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands; E-mail: m.vanderschroeff@erasmusmc.nl This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors disclose no conflicts of interest. Copyright © 2018 by Otology & Neurotology, Inc. Image copyright © 2010 Wolters Kluwer Health/Anatomical Chart Company

from #Audiology via xlomafota13 on Inoreader https://ift.tt/2GYkQhr
via IFTTT

Identification of four TMC1 variations in different Chinese families with hereditary hearing loss.

Identification of four TMC1 variations in different Chinese families with hereditary hearing loss.

Mol Genet Genomic Med. 2018 Apr 14;:

Authors: Wang H, Wu K, Guan J, Yang J, Xie L, Xiong F, Lan L, Wang D, Wang Q

Abstract
BACKGROUND: Variants in TMC1 (transmembrane channel-like 1) can cause both autosomal dominant and recessive hearing loss in human population. Mice with Tmc1 variants have been shown to be ideal animal models for gene therapy. In this article, we report four TMC1 variants in four different Chinese families and the follow-up auditory phenotype of a previously reported family.
METHODS: Four families with TMC1 variants, as well as a previously described family with TMC1 variant orthologous to the Beethoven mouse, were recruited in this study. A comprehensive auditory evaluation was performed on all ascertained family members. High-throughput sequencing was conducted using genomic DNA from the probands and other family members to identify probable deafness genes.
RESULTS: We identified four TMC1 (NM_138691.2) variations, including two pathogenic variants, c.1714G>A, and c.1253T>A, one likely pathogenic variant, c.[797T>C];[=], and one single nucleotide polymorphism (SNP), c.2276G>A. Among these variants, c.[797T>C];[=] is a novel likely pathogenic variant, and c.1714G>A and c.1253T>A are known pathogenic variants at the DFNB7/11 (DFNA36) locus. Phenotype-genotype correlation analysis of TMC1 variants showed that the TMC1 dominant variation-related phenotype was late-onset, progressive, high frequency to all frequency sensorineural hearing loss, while the TMC1 recessive variant was related to congenital all frequency sensorineural hearing impairment.
CONCLUSIONS: Two pathogenic, one likely pathogenic variants and one SNP of TMC1 were identified in four Chinese families with hereditary hearing loss, indicating that TMC1 may be a more frequent cause of hearing loss than expected. TMC1 variants related to hearing loss result in specific phenotypes. The TMC1 c.1253T>A (p.M418K) variation, homologous to the Tmc1 c. 1235 T> A (p.M412K) variant in Beethoven mice, was the second report of this variant in human patients with hearing loss, suggesting the possibility to translational gene therapy from Beethoven mice to human patients.

PMID: 29654653 [PubMed - as supplied by publisher]

from #Audiology via xlomafota13 on Inoreader https://ift.tt/2qA41P5
via IFTTT

Restoration of spatial hearing in adult cochlear implant users with single-sided deafness

Publication date: Available online 14 April 2018
Source:Hearing Research
Author(s): Ruth Y. Litovsky, Keng Moua, Shelly Godar, Alan Kan, Sara M. Misurelli, Daniel J. Lee
In recent years, cochlear implants (CIs) have been provided in growing numbers to people with not only bilateral deafness but also to people with unilateral hearing loss, at times in order to alleviate tinnitus. This study presents audiological data from 15 adult participants (ages 48 ± 12 years) with single sided deafness. Results are presented from 9/15 adults, who received a CI (SSD-CI) in the deaf ear and were tested in Acoustic or Acoustic + CI hearing modes, and 6/15 adults who are planning to receive a CI, and were tested in the unilateral condition only. Testing included (1) audiometric measures of threshold, (2) speech understanding for CNC words and AzBIO sentences, (3) tinnitus handicap inventory, (4) sound localization with stationary sound sources, and (5) perceived auditory motion. Results showed that when listening to sentences in quiet, performance was excellent in the Acoustic and Acoustic + CI conditions. In noise, performance was similar between Acoustic and Acoustic + CI conditions in 4/6 participants tested, and slightly worse in the Acoustic + CI in 2/6 participants. In some cases, the CI provided reduced tinnitus handicap scores. When testing sound localization ability, the Acoustic + CI condition resulted in improved sound localization RMS error of 29.2° (SD: ±6.7°) compared to 56.6° (SD: ±16.5°) in the Acoustic-only condition. Preliminary results suggest that the perception of motion direction, whereby subjects are required to process and compare directional cues across multiple locations, is impaired when compared with that of normal hearing subjects.



from #Audiology via ola Kala on Inoreader https://ift.tt/2ENswxf
via IFTTT

Restoration of spatial hearing in adult cochlear implant users with single-sided deafness

Publication date: Available online 14 April 2018
Source:Hearing Research
Author(s): Ruth Y. Litovsky, Keng Moua, Shelly Godar, Alan Kan, Sara M. Misurelli, Daniel J. Lee
In recent years, cochlear implants (CIs) have been provided in growing numbers to people with not only bilateral deafness but also to people with unilateral hearing loss, at times in order to alleviate tinnitus. This study presents audiological data from 15 adult participants (ages 48 ± 12 years) with single sided deafness. Results are presented from 9/15 adults, who received a CI (SSD-CI) in the deaf ear and were tested in Acoustic or Acoustic + CI hearing modes, and 6/15 adults who are planning to receive a CI, and were tested in the unilateral condition only. Testing included (1) audiometric measures of threshold, (2) speech understanding for CNC words and AzBIO sentences, (3) tinnitus handicap inventory, (4) sound localization with stationary sound sources, and (5) perceived auditory motion. Results showed that when listening to sentences in quiet, performance was excellent in the Acoustic and Acoustic + CI conditions. In noise, performance was similar between Acoustic and Acoustic + CI conditions in 4/6 participants tested, and slightly worse in the Acoustic + CI in 2/6 participants. In some cases, the CI provided reduced tinnitus handicap scores. When testing sound localization ability, the Acoustic + CI condition resulted in improved sound localization RMS error of 29.2° (SD: ±6.7°) compared to 56.6° (SD: ±16.5°) in the Acoustic-only condition. Preliminary results suggest that the perception of motion direction, whereby subjects are required to process and compare directional cues across multiple locations, is impaired when compared with that of normal hearing subjects.



from #Audiology via ola Kala on Inoreader https://ift.tt/2ENswxf
via IFTTT

Restoration of spatial hearing in adult cochlear implant users with single-sided deafness

Publication date: Available online 14 April 2018
Source:Hearing Research
Author(s): Ruth Y. Litovsky, Keng Moua, Shelly Godar, Alan Kan, Sara M. Misurelli, Daniel J. Lee
In recent years, cochlear implants (CIs) have been provided in growing numbers to people with not only bilateral deafness but also to people with unilateral hearing loss, at times in order to alleviate tinnitus. This study presents audiological data from 15 adult participants (ages 48 ± 12 years) with single sided deafness. Results are presented from 9/15 adults, who received a CI (SSD-CI) in the deaf ear and were tested in Acoustic or Acoustic + CI hearing modes, and 6/15 adults who are planning to receive a CI, and were tested in the unilateral condition only. Testing included (1) audiometric measures of threshold, (2) speech understanding for CNC words and AzBIO sentences, (3) tinnitus handicap inventory, (4) sound localization with stationary sound sources, and (5) perceived auditory motion. Results showed that when listening to sentences in quiet, performance was excellent in the Acoustic and Acoustic + CI conditions. In noise, performance was similar between Acoustic and Acoustic + CI conditions in 4/6 participants tested, and slightly worse in the Acoustic + CI in 2/6 participants. In some cases, the CI provided reduced tinnitus handicap scores. When testing sound localization ability, the Acoustic + CI condition resulted in improved sound localization RMS error of 29.2° (SD: ±6.7°) compared to 56.6° (SD: ±16.5°) in the Acoustic-only condition. Preliminary results suggest that the perception of motion direction, whereby subjects are required to process and compare directional cues across multiple locations, is impaired when compared with that of normal hearing subjects.



from #Audiology via xlomafota13 on Inoreader https://ift.tt/2ENswxf
via IFTTT

Restoration of spatial hearing in adult cochlear implant users with single-sided deafness

Publication date: Available online 14 April 2018
Source:Hearing Research
Author(s): Ruth Y. Litovsky, Keng Moua, Shelly Godar, Alan Kan, Sara M. Misurelli, Daniel J. Lee
In recent years, cochlear implants (CIs) have been provided in growing numbers to people with not only bilateral deafness but also to people with unilateral hearing loss, at times in order to alleviate tinnitus. This study presents audiological data from 15 adult participants (ages 48 ± 12 years) with single sided deafness. Results are presented from 9/15 adults, who received a CI (SSD-CI) in the deaf ear and were tested in Acoustic or Acoustic + CI hearing modes, and 6/15 adults who are planning to receive a CI, and were tested in the unilateral condition only. Testing included (1) audiometric measures of threshold, (2) speech understanding for CNC words and AzBIO sentences, (3) tinnitus handicap inventory, (4) sound localization with stationary sound sources, and (5) perceived auditory motion. Results showed that when listening to sentences in quiet, performance was excellent in the Acoustic and Acoustic + CI conditions. In noise, performance was similar between Acoustic and Acoustic + CI conditions in 4/6 participants tested, and slightly worse in the Acoustic + CI in 2/6 participants. In some cases, the CI provided reduced tinnitus handicap scores. When testing sound localization ability, the Acoustic + CI condition resulted in improved sound localization RMS error of 29.2° (SD: ±6.7°) compared to 56.6° (SD: ±16.5°) in the Acoustic-only condition. Preliminary results suggest that the perception of motion direction, whereby subjects are required to process and compare directional cues across multiple locations, is impaired when compared with that of normal hearing subjects.



from #Audiology via ola Kala on Inoreader https://ift.tt/2ENswxf
via IFTTT

Restoration of spatial hearing in adult cochlear implant users with single-sided deafness

Publication date: Available online 14 April 2018
Source:Hearing Research
Author(s): Ruth Y. Litovsky, Keng Moua, Shelly Godar, Alan Kan, Sara M. Misurelli, Daniel J. Lee
In recent years, cochlear implants (CIs) have been provided in growing numbers to people with not only bilateral deafness but also to people with unilateral hearing loss, at times in order to alleviate tinnitus. This study presents audiological data from 15 adult participants (ages 48 ± 12 years) with single sided deafness. Results are presented from 9/15 adults, who received a CI (SSD-CI) in the deaf ear and were tested in Acoustic or Acoustic + CI hearing modes, and 6/15 adults who are planning to receive a CI, and were tested in the unilateral condition only. Testing included (1) audiometric measures of threshold, (2) speech understanding for CNC words and AzBIO sentences, (3) tinnitus handicap inventory, (4) sound localization with stationary sound sources, and (5) perceived auditory motion. Results showed that when listening to sentences in quiet, performance was excellent in the Acoustic and Acoustic + CI conditions. In noise, performance was similar between Acoustic and Acoustic + CI conditions in 4/6 participants tested, and slightly worse in the Acoustic + CI in 2/6 participants. In some cases, the CI provided reduced tinnitus handicap scores. When testing sound localization ability, the Acoustic + CI condition resulted in improved sound localization RMS error of 29.2° (SD: ±6.7°) compared to 56.6° (SD: ±16.5°) in the Acoustic-only condition. Preliminary results suggest that the perception of motion direction, whereby subjects are required to process and compare directional cues across multiple locations, is impaired when compared with that of normal hearing subjects.



from #Audiology via ola Kala on Inoreader https://ift.tt/2ENswxf
via IFTTT